PEGBIO CO-B(02565) released annual performance, with research and development expenditures of 50.387 million yuan. It has successfully built a pipeline matrix covering seven investigational drugs for chronic diseases.

PEGBIO CO-B(02565) released its annual performance as of December 31, 2025, with a net other income of 189,000 yuan (RMB); research and development expenses of 50,387,000 yuan; and a basic loss per share of 0.55 yuan. As of the date of this announcement, significant progress has been made in technology innovation, product pipeline, and business operations in the United States and China. As of the date of this announcement, PEG Bio has successfully built a matrix covering seven investigational drug pipelines targeting chronic diseases. The company's core strategy focuses on the treatment of metabolic diseases and their complications. Through continuous innovation, internal evaluations show that multiple candidate drugs have the dual value potential of "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness. With the successful approval of its core product, Padacan (PB-119), for market listing in November 2025, the group will fully promote its commercialization in the Chinese market. In the future, the group will continue to work on aspects such as market access promotion after product listing, improvement of commercial operation systems, and enhancement of patient access to support market penetration and expansion of clinical use scenarios after product listing, gradually unlocking the product's value.